Finance entity
earnings is the sole category represented across all 1 tracked stories. Biopharmaceutical sector is most often covered alongside ChiNext, which appears in 1 of these 1 story. Biopharmaceutical sector appears in 1 tracked Finance story from September 4, 2026. The tracked stories average 2 original sources each.
Last mentioned: 2d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Biopharmaceutical sector is most often covered alongside ChiNext, which appears in 1 of these 1 story. Biopharmaceutical sector appears in 1 tracked Finance story from September 4, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Biopharmaceutical sector. Shared-story counts are live from our verified record — not editorial picks.
Chinese listed companies posted a record H1 2026 combined net profit of 3.58 trillion yuan ($532.7B), up 19.5% YoY, with growth accelerating in Q2. Tech-heavy boards led the surge — STAR Market profits rose 4.4x and ChiNext 32.7% — signaling a structurally driven, new-economy earnings recovery.
Biopharmaceutical sector is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
